Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection
about
Mucormycosis, pseudallescheriasis, and other uncommon mold infectionsRecent advances in the management of mucormycosis: from bench to bedsidePharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infectionsTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectivePosaconazole: an oral triazole with an extended spectrum of activityEfficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.Intracellular concentrations of posaconazole in different compartments of peripheral blood.Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based methodRandomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.Recent advances in the treatment of mucormycosis.Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantationPractice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapyClinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Relevance of timing for determination of posaconazole plasma concentrationsHuman Fungal Pathogens of Mucorales and Entomophthorales.Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature.Combination therapy for mucormycosis: why, what, and how?Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit.Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease.In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales OrderTherapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome.New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients.Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.Current options in antifungal pharmacotherapy.Nephrotoxicity in the setting of invasive fungal diseases.Antifungal therapeutic drug monitoring: established and emerging indications.
P2860
Q24603297-3B4DCDD7-07DA-4FD3-AF4D-98AD59CFD8F6Q24642450-95306AE5-09B4-4739-B4E2-13A163434DD3Q26771180-6AB4FE6B-7AF1-492D-9004-23E8DDAA379FQ27009221-B1EBB7DD-7118-40BF-A527-09C84BF1D534Q28291282-2E8B50F6-4423-45B5-8DAD-08AB922806F5Q33613758-9277EF02-ADCB-4CEF-993D-A358985BA179Q33798286-6D5FD73D-140E-48A8-A503-B7612C03FBC8Q33962775-2780DA87-C2C3-4662-AD2C-3CD7B0555B77Q34108484-EDF58DFE-FE91-472F-8321-8FDFB947A5CFQ34151170-9308A8CF-66F3-4EBE-813B-5A39D4A014B7Q34161213-8C72F91C-31D1-413F-B5B1-912831469CFFQ34309527-D484030B-EB43-46D6-897E-7F2A8CAB4409Q34452574-3F519BEA-8F83-4531-8732-FF53F1728B14Q34532546-0FBCA034-2398-4CF5-9EAC-5E630D2B035FQ34596750-92B6C260-C689-48A3-9596-37C7DF0C545DQ34596761-168B18BE-9E25-4A9A-9601-6439045DBE21Q34680655-3C05BD72-16A6-47B3-95A8-6CB32D73883AQ34754956-EA02AC5F-4E31-4408-91CD-58A4FBD76C85Q35026481-BB669171-1BAD-4442-8822-8CC8533F6562Q35065721-44E3C967-7C01-4D0F-AFE3-40AE220822EFQ35245238-AF4C6D11-4CD8-4E7C-B00D-3487AB9D925EQ35262607-CE247A5D-C11C-44BC-9256-90628BD70FCBQ35635971-3B0F139B-AF0B-47B3-8F15-5499A8FB8EE1Q35941414-49EF1148-1BDD-49BF-9C66-7316D737F45DQ35959480-2601A4C8-9C22-47B7-A2B5-1AAAD7A88E5CQ35974333-7EA84F45-AC26-42AD-A81C-2C7904ED464CQ36018743-877AD03E-AD8C-485D-98EA-B28B0BF0AEF2Q36171677-108285A4-A751-4CCF-908A-974F9F90CAF3Q36171717-5C6839CF-3916-43F7-9158-0B4D236E7F0EQ36276966-054D01A7-64FD-4B2B-B632-E2ECCCC658ADQ36290764-FAD03229-8170-4CEA-8913-9084021B03E9Q36396203-9F9A1509-3431-42A7-A274-55DA614A0D83Q36597431-65F0DA7A-364A-4A16-ABDB-35E68B796EDBQ36613885-13174F20-82D5-471E-8287-27D39C6B9541Q37043539-5C8C9EA5-25DE-44A3-82F3-2F739291ADCCQ37055215-DA374401-A779-403C-B057-45FE65682B79Q37115829-D7CA0A56-D1E0-457A-9F5D-B29B4BA06A8FQ37151326-748D275B-491E-43FF-A5AA-06911826ADFCQ37159573-1E510EB2-BAB8-460E-AAD4-892072B018B6Q37310029-49395DC7-9E39-4EA3-BD8C-FDF3ECCA9673
P2860
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Pharmacokinetics, safety, and ...... tory invasive fungal infection
@ast
Pharmacokinetics, safety, and ...... tory invasive fungal infection
@en
Pharmacokinetics, safety, and ...... tory invasive fungal infection
@nl
type
label
Pharmacokinetics, safety, and ...... tory invasive fungal infection
@ast
Pharmacokinetics, safety, and ...... tory invasive fungal infection
@en
Pharmacokinetics, safety, and ...... tory invasive fungal infection
@nl
prefLabel
Pharmacokinetics, safety, and ...... tory invasive fungal infection
@ast
Pharmacokinetics, safety, and ...... tory invasive fungal infection
@en
Pharmacokinetics, safety, and ...... tory invasive fungal infection
@nl
P2093
P2860
P1476
Pharmacokinetics, safety, and ...... tory invasive fungal infection
@en
P2093
A Burchardt
A J Ullmann
D P Kontoyiannis
G Corcoran
M Martinho
O A Cornely
P2860
P304
P356
10.1128/AAC.50.2.658-666.2006
P407
P577
2006-02-01T00:00:00Z